22157.jpg
Antisense Oligonucleotide Therapeutics Pipeline Insight Report 2021: Focus on 15+ Companies and 15+ Pipeline Drugs
October 18, 2021 11:23 ET | Research and Markets
Dublin, Oct. 18, 2021 (GLOBE NEWSWIRE) -- The "Antisense Oligonucleotide Therapeutics - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering. This "Antisense...
22157.jpg
Outlook on the mRNA Global Market and Therapeutics to 2026
October 06, 2021 06:43 ET | Research and Markets
Dublin, Oct. 06, 2021 (GLOBE NEWSWIRE) -- The "mRNA: Therapeutics and Global Markets 2021-2026" report has been added to ResearchAndMarkets.com's offering. The global market for mRNA therapeutics...
22157.jpg
Outlook on the Antisense Oligonucleotide Therapeutics Global Market to 2030 - Featuring Biogen, Bio-Path Holdings and Sarepta Therapeutics Among Others
April 01, 2021 05:48 ET | Research and Markets
Dublin, April 01, 2021 (GLOBE NEWSWIRE) -- The "Antisense Oligonucleotide Therapeutics Market by Target Indication, Type of Therapy, Type of Molecule Type of Generation and Key Geographies: Industry...
logo long.jpg
Global CNS Specific Antisense Oligonucleotide Market to Surpass US$ 6.8 Billion by 2026 – Coherent Market Insights
February 08, 2019 08:30 ET | CMI
SEATTLE, Feb. 08, 2019 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global CNS specific antisense oligonucleotide market is valued at US$ 883.7 million in 2017, and is projected to...
GeneTx Biotherapeutics receives FDA orphan-drug designation for Angelman syndrome treatment
March 27, 2018 13:26 ET | GeneTx Biotherapeutics LLC.
DOWNERS GROVE, Ill., March 27, 2018 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration has granted orphan-drug designation to GeneTx Biotherapeutics LLC’s GTX-101 for the treatment of...
Prosensa Holding B.V. Logo
Prosensa Awarded $200,000 Research Grant from PPMD
June 27, 2014 08:00 ET | Prosensa Holding N.V.
Leiden, The Netherlands, June 27, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high...